ZA201506440B - Halogenopyrazoles as inhibitors of thrombin - Google Patents
Halogenopyrazoles as inhibitors of thrombinInfo
- Publication number
- ZA201506440B ZA201506440B ZA2015/06440A ZA201506440A ZA201506440B ZA 201506440 B ZA201506440 B ZA 201506440B ZA 2015/06440 A ZA2015/06440 A ZA 2015/06440A ZA 201506440 A ZA201506440 A ZA 201506440A ZA 201506440 B ZA201506440 B ZA 201506440B
- Authority
- ZA
- South Africa
- Prior art keywords
- halogenopyrazoles
- thrombin
- inhibitors
- Prior art date
Links
- 108090000190 Thrombin Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229960004072 thrombin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789358P | 2013-03-15 | 2013-03-15 | |
| US201361899588P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/000058 WO2014149139A2 (en) | 2013-03-15 | 2014-03-17 | Halogenopyrazoles as inhibitors of thrombin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201506440B true ZA201506440B (en) | 2019-06-26 |
Family
ID=51538179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/06440A ZA201506440B (en) | 2013-03-15 | 2015-09-02 | Halogenopyrazoles as inhibitors of thrombin |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9951025B2 (enExample) |
| EP (1) | EP2970141B1 (enExample) |
| JP (3) | JP6479749B2 (enExample) |
| KR (1) | KR20150130405A (enExample) |
| CN (2) | CN105209440B (enExample) |
| AU (2) | AU2014238478B2 (enExample) |
| BR (1) | BR112015023214A8 (enExample) |
| CA (1) | CA2902431A1 (enExample) |
| ES (1) | ES2791749T3 (enExample) |
| HK (1) | HK1214252A1 (enExample) |
| IL (1) | IL240763B (enExample) |
| MX (1) | MX373646B (enExample) |
| RU (1) | RU2015144193A (enExample) |
| SG (2) | SG10201707486XA (enExample) |
| WO (2) | WO2014149139A2 (enExample) |
| ZA (1) | ZA201506440B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1214252A1 (zh) * | 2013-03-15 | 2016-07-22 | Verseon Corporation | 作為凝血酶抑制劑的鹵代吡唑 |
| CN110101699A (zh) | 2013-03-15 | 2019-08-09 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物 |
| PL3261639T3 (pl) * | 2015-02-27 | 2022-12-19 | Verseon International Corporation | Podstawione związki pirazolowe jako inhibitory proteazy serynowej |
| MX2021012250A (es) | 2019-04-11 | 2022-01-18 | Angion Biomedica Corp | Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol. |
| CN112062692A (zh) * | 2019-06-11 | 2020-12-11 | 太仓市茜泾化工有限公司 | 一种乙氧甲叉氰基乙酸乙酯的制备方法 |
| CN112986065B (zh) * | 2021-02-08 | 2021-08-31 | 杭州同创医学检验实验室有限公司 | 一种用于血细胞分析仪的全血质控品及其制备方法 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US188918A (en) * | 1877-03-27 | Improvement in towel-racks | ||
| US1323438A (en) * | 1919-12-02 | of niagara falls | ||
| BE627394A (enExample) | 1962-01-23 | |||
| BE793955A (fr) | 1972-01-15 | 1973-07-12 | Merck Patent Gmbh | Arylpiperazines et leur procede de preparation |
| DE2409753A1 (de) | 1974-03-01 | 1975-09-11 | Basf Ag | Substituierte pyrazole |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| IL82542A0 (en) | 1986-05-23 | 1987-11-30 | Smithkline Beckman Corp | Triazole derivatives,their preparation and pharmaceutical compositions containing them |
| JPH089541B2 (ja) | 1988-03-07 | 1996-01-31 | 三井東圧化学株式会社 | ピラゾール類を主成分とする脳浮腫抑制剤 |
| JP2784925B2 (ja) * | 1988-09-07 | 1998-08-13 | 日本農薬株式会社 | ３又は５−フェニルピラゾール類又はその塩及び除草剤 |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JP3810097B2 (ja) | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| CZ294630B6 (cs) | 1993-11-30 | 2005-02-16 | G. D. Searle & Co. | Substituované pyrazolylbenzensulfonamidy pro léčení zánětů |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| ES2219670T3 (es) | 1994-11-10 | 2004-12-01 | Millennium Pharmaceuticals, Inc. | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. |
| US5733955A (en) | 1995-02-10 | 1998-03-31 | The Goodyear Tire & Rubber Company | Asphalt cement modification |
| JP3663522B2 (ja) * | 1995-08-12 | 2005-06-22 | 日本農薬株式会社 | 植物生育調節用組成物及びその使用方法 |
| US5756529A (en) | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
| WO1997013756A1 (en) | 1995-10-13 | 1997-04-17 | Otsuka Kagaku Kabushiki Kaisha | Pyrazole derivatives and insecticidal compositions containing the same as active ingredient |
| US5792761A (en) * | 1996-08-12 | 1998-08-11 | Merck & Co., Inc. | Thrombin inhibitors |
| DE69717147T2 (de) * | 1996-08-12 | 2003-07-24 | Merck & Co., Inc. | Thrombin inhibitoren |
| DE19632773A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Thrombininhibitoren |
| GB9622370D0 (en) | 1996-10-28 | 1997-01-08 | Merck Sharp & Dohme | Therapeutic agents |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| ATE443698T1 (de) | 1996-12-23 | 2009-10-15 | Bristol Myers Squibb Pharma Co | Stickstoffhaltige heterocyclen als faktor xa- hemmer |
| ID22380A (id) | 1997-03-21 | 1999-10-07 | Novartis Ag | Turunan-turunan pirazol sebagai herbisida |
| WO2000009500A2 (en) | 1998-08-11 | 2000-02-24 | Nihon Bayer Agrochem K.K. | Nematicidal pyrazoles |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
| AU5020400A (en) * | 1999-05-20 | 2000-12-12 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| EE200200065A (et) | 1999-08-12 | 2003-04-15 | Pharmacia Italia S.P.A. | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| RU2002110295A (ru) | 1999-09-17 | 2003-12-10 | Милленниум Фармасьютикалс, Инк. (Us) | Ингибиторы фактора Ха |
| CA2390113A1 (en) | 1999-12-02 | 2001-06-07 | Maurizio Schwarzenbach | Aminoheterocyclylamides as pesticides and antiparasitic agents |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｓｒｃおよび他のプロテインキナーゼのインヒビター |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| SI21097A (sl) | 2001-12-04 | 2003-06-30 | Univerza V Ljubljani | Inhibitorji trombina |
| SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| EP1509505A2 (en) * | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
| JP2003313103A (ja) * | 2002-02-20 | 2003-11-06 | Sankyo Agro Kk | ４−アシルアミノピラゾール誘導体を有効成分として含有する農薬 |
| GB0214139D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| DE10229070A1 (de) | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| AR041508A1 (es) | 2002-08-09 | 2005-05-18 | Astra Ab | Compuestos con actividad en los receptores de glutamato metabotropicos |
| AU2003274025A1 (en) | 2002-10-17 | 2004-05-04 | Syngenta Participations Ag | Pyridine derivatives useful as herbicides |
| US7192976B2 (en) | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| JP4585448B2 (ja) | 2002-12-23 | 2010-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 第Ｘａ因子阻害剤としてのピラゾール−誘導体 |
| US20060229335A1 (en) * | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| JP2004231528A (ja) * | 2003-01-28 | 2004-08-19 | Sankyo Agro Kk | アミド誘導体 |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| ATE482200T1 (de) * | 2003-05-01 | 2010-10-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen |
| EP1633348B1 (en) * | 2003-05-02 | 2008-10-08 | Elan Pharmaceuticals, Inc. | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| EP1479679A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Triazole-derivatives as factor Xa inhibitors |
| EP1697342A2 (en) | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| BRPI0414313A (pt) | 2003-09-11 | 2006-11-07 | Kemia Inc | inibidores de citocinas |
| WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| KR101258504B1 (ko) * | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| EP2368881A1 (en) | 2005-01-10 | 2011-09-28 | University of Connecticut | Heteropyrazole analogs acting on cannabinoid receptors |
| JPWO2006109846A1 (ja) | 2005-04-06 | 2008-11-20 | 武田薬品工業株式会社 | トリアゾール誘導体およびその用途 |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| CN100427481C (zh) | 2005-05-26 | 2008-10-22 | 沈阳化工研究院 | 一种芳基醚类化合物及其制备与应用 |
| JP2009518442A (ja) | 2005-12-05 | 2009-05-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物 |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| MX2009000602A (es) | 2006-07-17 | 2009-01-28 | Boehringer Ingelheim Int | Nuevas indicaciones para los inhibidores directos de la trombina en el campo cardiovascular. |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| WO2008023235A1 (en) * | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
| WO2008062739A1 (en) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US20100144793A1 (en) * | 2006-11-24 | 2010-06-10 | Ac Immune Sa | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| US7795249B2 (en) | 2006-12-22 | 2010-09-14 | Millennium Pharmaceuticals, Inc. | Certain pyrazoline derivatives with kinase inhibitory activity |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
| GB0714129D0 (en) | 2007-07-19 | 2007-08-29 | Smithkline Beecham Corp | compounds |
| WO2009020137A1 (ja) * | 2007-08-06 | 2009-02-12 | Dainippon Sumitomo Pharma Co., Ltd. | アミノピラゾールアミド誘導体 |
| US8334301B2 (en) | 2007-09-28 | 2012-12-18 | Takeda Pharmaceutical Company Limited | 5-Membered heterocyclic compound |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| EP2732819B1 (en) | 2008-02-07 | 2019-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| CN102088973A (zh) | 2008-05-15 | 2011-06-08 | 杜克大学 | 与热休克转录因子激活化合物及其靶标有关的组合物和方法 |
| EP2300435A2 (en) | 2008-05-19 | 2011-03-30 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| CN102149379A (zh) | 2008-07-10 | 2011-08-10 | 安吉翁生物医药有限公司 | 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物 |
| US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| EP2374791A1 (de) * | 2008-08-14 | 2011-10-12 | Bayer CropScience Aktiengesellschaft | Insektizide 4-Phenyl-1H-pyrazole |
| MX2011001612A (es) | 2008-08-19 | 2011-03-04 | Boehringer Ingelheim Int | Dabigatran para cateterismo cardiaco con intervencion percutanea. |
| EP2328581A1 (en) | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| EP2331096A1 (en) | 2008-08-19 | 2011-06-15 | Boehringer Ingelheim International GmbH | Dabigatran in tumour therapy |
| SI2427436T1 (sl) | 2009-05-07 | 2013-04-30 | Grunenthal Gmbh | Substituirani aromatski karboksamidni in sečninski derivati kot ligandi vaniloidnega receptorja |
| SG10201502484SA (en) * | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| CN101851207B (zh) | 2010-06-11 | 2012-01-25 | 扬州康伊尔医药科技有限公司 | 抗病毒化合物中间体1-酰基-吡唑-3-羧酸及其制备方法 |
| EP2604602A4 (en) * | 2010-08-11 | 2013-12-18 | Taisho Pharmaceutical Co Ltd | HETEROARYL PYRAZOLE DERIVATIVE |
| CN105360132A (zh) * | 2010-11-03 | 2016-03-02 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
| EP2697196A1 (en) | 2011-04-13 | 2014-02-19 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| JP6113151B2 (ja) | 2011-05-17 | 2017-04-12 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症 |
| US9371307B2 (en) | 2011-09-12 | 2016-06-21 | The Johns Hopkins University | Serine protease inhibitors |
| WO2013049591A2 (en) | 2011-09-29 | 2013-04-04 | Verseon Corporation | Dual inhibitor compounds and methods of use thereof |
| US9139564B2 (en) | 2011-12-27 | 2015-09-22 | Ironwood Pharmaceuticals, Inc. | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators |
| EP2807157A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| CN110101699A (zh) | 2013-03-15 | 2019-08-09 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物 |
| HK1214252A1 (zh) | 2013-03-15 | 2016-07-22 | Verseon Corporation | 作為凝血酶抑制劑的鹵代吡唑 |
-
2014
- 2014-03-17 HK HK16102083.6A patent/HK1214252A1/zh unknown
- 2014-03-17 KR KR1020157027980A patent/KR20150130405A/ko not_active Ceased
- 2014-03-17 MX MX2015011567A patent/MX373646B/es active IP Right Grant
- 2014-03-17 AU AU2014238478A patent/AU2014238478B2/en active Active
- 2014-03-17 EP EP14769269.3A patent/EP2970141B1/en active Active
- 2014-03-17 JP JP2016500154A patent/JP6479749B2/ja active Active
- 2014-03-17 BR BR112015023214A patent/BR112015023214A8/pt not_active IP Right Cessation
- 2014-03-17 ES ES14769269T patent/ES2791749T3/es active Active
- 2014-03-17 CN CN201480027721.XA patent/CN105209440B/zh active Active
- 2014-03-17 CN CN201910623548.4A patent/CN110423221A/zh active Pending
- 2014-03-17 SG SG10201707486XA patent/SG10201707486XA/en unknown
- 2014-03-17 RU RU2015144193A patent/RU2015144193A/ru not_active Application Discontinuation
- 2014-03-17 SG SG11201506757TA patent/SG11201506757TA/en unknown
- 2014-03-17 WO PCT/US2014/000058 patent/WO2014149139A2/en not_active Ceased
- 2014-03-17 US US14/776,641 patent/US9951025B2/en active Active
- 2014-03-17 CA CA2902431A patent/CA2902431A1/en not_active Abandoned
- 2014-03-18 WO PCT/US2014/030937 patent/WO2014146059A1/en not_active Ceased
-
2015
- 2015-08-23 IL IL24076315A patent/IL240763B/en not_active IP Right Cessation
- 2015-09-02 ZA ZA2015/06440A patent/ZA201506440B/en unknown
-
2018
- 2018-02-27 US US15/907,045 patent/US20180186751A1/en not_active Abandoned
- 2018-10-19 AU AU2018250514A patent/AU2018250514A1/en not_active Abandoned
-
2019
- 2019-02-06 JP JP2019019308A patent/JP2019081782A/ja active Pending
-
2020
- 2020-06-16 JP JP2020103499A patent/JP2020158522A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014149139A2 (en) | 2014-09-25 |
| JP2019081782A (ja) | 2019-05-30 |
| EP2970141A2 (en) | 2016-01-20 |
| JP2016512243A (ja) | 2016-04-25 |
| US20160046585A1 (en) | 2016-02-18 |
| CN110423221A (zh) | 2019-11-08 |
| MX373646B (es) | 2020-04-02 |
| EP2970141B1 (en) | 2020-02-26 |
| CN105209440B (zh) | 2019-07-23 |
| WO2014146059A1 (en) | 2014-09-18 |
| AU2014238478A1 (en) | 2015-09-10 |
| IL240763A0 (en) | 2015-10-29 |
| KR20150130405A (ko) | 2015-11-23 |
| HK1214252A1 (zh) | 2016-07-22 |
| US20180186751A1 (en) | 2018-07-05 |
| US9951025B2 (en) | 2018-04-24 |
| AU2014238478B2 (en) | 2018-07-19 |
| BR112015023214A2 (pt) | 2017-07-18 |
| CN105209440A (zh) | 2015-12-30 |
| JP6479749B2 (ja) | 2019-03-06 |
| SG11201506757TA (en) | 2015-09-29 |
| CA2902431A1 (en) | 2014-09-25 |
| SG10201707486XA (en) | 2017-10-30 |
| AU2018250514A1 (en) | 2018-11-15 |
| WO2014149139A3 (en) | 2014-11-27 |
| RU2015144193A (ru) | 2017-04-24 |
| JP2020158522A (ja) | 2020-10-01 |
| IL240763B (en) | 2019-11-28 |
| ES2791749T3 (es) | 2020-11-05 |
| EP2970141A4 (en) | 2016-08-31 |
| MX2015011567A (es) | 2016-04-25 |
| BR112015023214A8 (pt) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279682A (en) | Benzoquinolone compounds as VMAT2 inhibitors | |
| PL3305778T3 (pl) | Inhibitory kalikreiny osoczowej | |
| PL3033336T3 (pl) | Inhibitory kalikreiny w plaźmie | |
| PT3057959T (pt) | Inibidores de adn-pk | |
| SG11201507203RA (en) | Dna-pk inhibitors | |
| EP2948450A4 (en) | METALLOENZYMINHIBITORVERBINDUNGEN | |
| ZA201506156B (en) | Novel inhibitors | |
| IL245245A0 (en) | New dgat2 inhibitors | |
| EP3003372A4 (en) | Inhibitors of complement factor h | |
| IL246230A0 (en) | Amines thf quinazoline as pde1 inhibitors | |
| EP2994124A4 (en) | INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES | |
| ZA201506440B (en) | Halogenopyrazoles as inhibitors of thrombin | |
| IL244617A0 (en) | Benzoquinolone compounds as vmat2 inhibitors | |
| PL2888228T3 (pl) | Inhibitory oddziaływania CD40-TRAF6 | |
| ZA201508010B (en) | Inhibitors of metastasis | |
| GB201312311D0 (en) | Uses of enzyme inhibitors | |
| EP2959896A4 (en) | INHIBITOR OF PHOSPHORYLATION OF PROTEIN T | |
| GB201320835D0 (en) | HIF inhibitors |